
Biomarin Pharmaceutical Inc. expects European patients to begin receiving its gene therapy for a life-threatening blood-clotting disorder before the end of the year, raising the drugmaker’s hopes it can succeed where rival Bluebird Bio Inc. faltered.
The one-time infusion for hemophilia could gain European approval at the end of August after getting a key recommendation in June from a regulatory committee, Biomarin Chief Commercial Officer Jeff Ajer said in an interview. The company will then make a country-by-country push to persuade health systems to pay for it, starting with Germany, with broader agreements likely taking about a year to clinch, he said.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app